CRMPs: Critical molecules for neurite morphogenesis and neuropsychiatric diseases

Molecular Psychiatry

Volumn 20, Issue 9, 2015, Pages 1037-1045

  Quach, T T ^a,b   Honnorat, J ^a,c,d   Kolattukudy, P E ^e   Khanna, R ^f   Duchemin, A M ^g  

^a LYON NEUROSCIENCE RESEARCH CENTER   (France)

^b OHIO STATE UNIVERSITY   (United States)

^c HÔPITAL NEUROLOGIQUE   (France)

^d UNIVERSITÉ LYON 1   (France)

^e UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 1; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; COLLAPSIN RESPONSE MEDIATOR PROTEIN 4; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5; UNCLASSIFIED DRUG; NERVE PROTEIN;

ALZHEIMER DISEASE; ANIMAL MODEL; CELL SPECIFICITY; DENDRITIC CELL; DISEASE MARKER; EPILEPSY; HUMAN; MENTAL DISEASE; MOLECULAR PATHOLOGY; MOOD DISORDER; NERVE CELL DIFFERENTIATION; NERVE CELL NETWORK; NERVE FIBER; NERVE FIBER GROWTH; NEURITE; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROPSYCHIATRY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; SCHIZOPHRENIA; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; CYTOLOGY; DENDRITE; GENETIC ASSOCIATION STUDY; GENETICS; METABOLISM; MORPHOGENESIS; MOUSE; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DENDRITES; GENETIC ASSOCIATION STUDIES; HUMANS; MICE; MORPHOGENESIS; NERVE TISSUE PROTEINS; NEUROGENESIS; NEURONS;

EID: 84940439562     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.77     Document Type: Review

References (129)

1. Tessier-Lavigne M, Kolodkin AL. Neuronal guidance. Cold Spring Harb Perspect Biol 2011; 3: 1-14.
2. Barnes AP, Polleux F. Establishment of axon-dendrite polarity in developing neurons. Ann Rev Neurosci 2009; 32: 347-381.
3. Cheng P, Poo MM. Early events in Axon/Dendrite polarization. Annu Rev Neurosci 2012; 35: 181-201.
4. Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J. Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurol 2003; 28: 51-64.
5. Schmidt EF, Strittmatter SM. The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol 2007; 600: 1-11.
6. Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM. Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature 1995; 376: 509-514.
7. Minturn JE, Fryer HJ, Geschwind DH, Hockfield S. Toad-64 a gene expressed early in neuronal differentiation in the rat is related to unc-33, a C-elegans gene involved in axon outgrowth. J Neurosci 1995; 15: 6757-6766.
8. Byk T, Dobransky T, Sobel A. Identification and molecular characterization of Unc-33-like phosphoprotein (Ulip), a putative mammalian homolog of the axo-nal guidance-associate unc-33 gene product. J Neurosci 1996; 16: 688-701.
9. Quach TT, Rong Y, Belin MF, Duchemin AM, Akaoka H, Ding S et al. Molecular cloning and expression of a new unc-33 like cDNA from rat brain and its relation to paraneoplastic neurological syndromes. Mol Brain Res 1997; 46: 329-332.
10. Wang LH, Strittmatter SM. A family of rat CRMP genes is differentially expressed in the nervous system. J Neurosci 1996; 16: 6197-6207.
11. Byk T, Ozon S, Sobel A. The Ulip family phosphoproteins: common and specific properties. Eur J Biochem 1998; 254: 14-24.
12. Inatome R, Tsujimura T, Hitomi T, Mitsui N, Hermann P, Kuroda S et al. Identification of CRAM, a novel unc-33 gene family protein that associates with CRMP3 and protein tyrosine kinase(s) in the developing rat brain. J Biol Chem 2000; 275: 27291-27302.
13. Quinn CC, Chen E, Kinjo TG, Bell AW, Eliott RC, McPherson PS et al. TUC-4b, a novel TUC family variant, regulates neurite outgrowth and associates with vesicles in the growth cone. J Neurosci 2003; 23: 2815-2823.
14. Fukata Y, Itoh TJ, Kimura T, Menager C, Nishimara T, Shiromizu T et al. CRMP2 binds to tubulin heterodimers to promote microtubule assembly. Nat Cell Biol 2002; 4: 583-591.
15. Uchida Y, Ohshima T, Yamashita N, Ogawara M, Sasaki Y, Nakamura F et al. Sema3A signaling mediated by Fyn-dependent tyrosine phosphorylation of CRMP2 at tyrosine 32. J Biol Chem 2009; 284: 27393-27401.
16. Leung T, Ng Y, Cheong A, Ng CH, Tan L, Hall C et al. P80 ROK alpha binding protein is a novel variant of CRMP1 which associates with CRMP2 and modulates RhoA-induced neuronal morphology. FEBS Lett 2002; 523: 445-449.
17. Yamashita N, Morita A, Uchida Y, Nakamura F, Usui H, Ohshima T et al. Regulation of spine development by semaphorin 3A through cyclin-dependent kinase 5 phosphorylation of collapsin response mediator protein 1. J Neurosci 2007; 14: 12546-12554.
18. Yamashita N, Uchida Y, Ohshima T, Hira S, Nakamura F, Taniguchi M et al. CRMP1 mediates reelin signaling in cortical neuronal migration. J Neurosci 2006; 26: 13357-13362.
19. Kawano Y, Yoshimura T, Tsuboi D, Kawabata S, Kaneko-Kawano T, Shirataki H et al. CRMP2 is involved in kinesin-dependent transport of the Sra-1/WAVE1 complex and axon formation. Mol Cell Biol 2005; 25: 9920-9935.
20. Rosslenbroich V, Dai L, Baader SL, Gieselmann V, Kappler J. Collapsin response mediator protein-4 regulates F-actin bundling. Exp Cell Res 2005; 310: 434-444.
21. Cole AR, Knebel A, Morrice NA, Robertson LA, Irving AJ, Connolly CN et al. GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem 2004; 279: 50176-50180.
22. Cole A. GSK-3 substrates in mood disorders and schizophrenia. FEBS J 2013; 280: 5213-5227.
23. Brennand JK, Simone A, Tran N, Gage FH. Modeling psychiatric disorders at the cellular and network levels. Mol Psychiatry 2012; 17: 1239-1252.
24. Medina M, Avila J. New insights into the role of GSK-3 in Alzheimer's disease. Expert Opin Ther Targets 2014; 18: 69-77.
25. Uchida Y, Ohshima T, Sasaki Y, Suzuki H, Yanai S, Yamashita N et al. Sema-phorin3A signaling is mediated via sequential Cdk5 and GSK3-β phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease. Genes Cell 2005; 10: 165-179.
26. Yashimata N, Mosinger B, Roy A, Miyazaki M, Ugagin K, Sasaki Y et al. CRMP5 regulates dendritic development and synaptic plasticity in the cerebellar Purkinje cells. J Neurosci 2011; 31: 1773-1779.
27. Yamashita N, Goshima Y. CRMPs regulate neuronal development and plasticity by switching their phosphorylation status. Mol Neurobiol 2012; 16: 933-944.
28. Brittain JM, Piekarz AD, Wang Y, Kondo T, Cummins TR, Khanna R. An atypical role for CRMP2 in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J Biol Chem 2009; 284: 31375-31390.
29. Quach TT, Wilson SM, Rogemond V, Chounlamountri N, Kolattukudy PE, Martinez S et al. Mapping CRMP3 domains involved in dendrite morphogenesis and voltage-gated calcium channel regulation. J Cell Sci 2013; 126: 4262-4273.
30. Alabed Y, Pool M, Ong Tone S, Fournier A. Identification of CRMP4 as a convergent regulator of axon outgrowth inhibition. J Neurosci 2007; 27: 1702-1711.
31. Bretin S, Reibel S, Charier E, Maus-Motti M, Auvergon N, Thevenoux A et al. Differential expression of CRMP1, CRMP2A, CRMP2B and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. J Comp Neurol 2005; 486: 1-17.
32. Quach TT, Mosinger B, Ricard D, Copeland NC, Gilbert DJ, Jenkins JA et al. Col-lapsin response mediator protein 3/unc33-like protein 4 gene: organization, chromosomal mapping and expression in the developing mouse brain. Gene 2000; 242: 175-182.
33. Kwiatkowski AV, Rubinson DA, Dent EW, Van Veen JE, Leslie JD, Zhang J et al. Ena/VASP is required for neuritogenesis in the developing cortex. Neuron 2007; 56: 441-455.
34. Brot S, Smaoune H, Youssef-Issa M, Malleval C, Benetollo C, Besancon R et al. CRMP5 phosphorylation at Threonine 516 regulates neurite outgrowth inhibition. Eur J Neurosci 2014; 40: 3010-3020.
35. Brot S, Auger C, Bentata R, Rogemond V, Menigoz S, Chounlamountri N et al. CRMP5 induces mitophagy, thereby regulating mitochondrion numbers in dendrites. J Biol Chem 2014; 289: 2261-2276.
36. Brot S, Rogemond V, Perrot V, Chounlamountri N, Auger C, Honnorat J et al. CRMP5 interacts with tubulin to inhibit neurite outgrowth, thereby modulating the function of CRMP2. J Neurosci 2010; 30: 10639-10654.
37. Niisato E, Nagai J, Yamashita N, Abe T, Kiyonari H, Goshima Y et al. CRMP4 suppresses apical dendrite bifurcation of CA1 pyramidal neurons in the mouse hippocampus. Dev Neurobiol 2012; 72: 1447-1457.
38. Yamashita N, Ohshima T, Nakamura F, Kolattukudy P, Honnorat J, Goshima Y. Phosphorylation of CRMP2 is involved in proper dendritic field organization. J Neurosci 2012; 32: 1360-1365.
39. Inagaki N, Chihara K, Arimura N, Menager C, Kawano Y, Matsuo N et al. CRMP2 induces axons in cultured hippocampal neurons. Nat Neurosci 2001; 4: 781-782.
40. Yoshimura T, Kawano Y, Arimura N, Kikuchi A, Kaibuchi K. GSK-3β regulates phosphorylation of CRMP2 and neuronal polarity. Cell 2005; 120: 137-149.
41. Nishimura T, Fukata Y, Kato K, Yamaguchi T, Matsuura Y, Kamiguchi H et al. CRMP-2 regulates polarized Num-mediated endocytosis for axon growth. Nat Cell Biol 2003; 5: 819-825.
42. Chi XX, Schmutzier BS, Brittain JM, Wang Y, Hintgen C, Nicol GD et al. Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by CRMP2 in sensory neurons. J Cell Sci 2009; 122: 4351-4362.
43. Quach TT, Duchemin AM, Rogemond V, Aguera M, Honnorat J, Belin MF et al. Involvement of collapsin response mediator proteins in the neurite extension produced by neurotrophins in dorsal root ganglion neurons. Mol Cell Neurosci 2004; 25: 433-443.
44. Charrier E, Mosinger B, Meisserel C, Aguera M, Rogemond V, Reibel S et al. Transient alterations in granule cells proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1-/-mice. Genes Cells 2006; 11: 1337-1352.
45. Ghogha A, Bruun DA, Lein P. Inducing dendritic growth in cultured sympathetic neurons. J Vis Exp 2012; 61: e3546.
46. Su SK, Chien WL, Fu WM, Yu IS, Huang HP, Huang PH et al. Mice deficient in CRMP1 exhibit impaired long-term potentiation and impaired spatial learning and memory. J Neurosci 2007; 27: 2513-2524.
47. Yamashita N, Takashi A, Takao K, Yamamoto T, Kolattukudy, Miyakawa T. Mice lacking CRMP1 manifest hyperactivity, impaired learning and memory, and impaired prepulse inhibition. Front Behav Neurosci 2013; 7: 216.
48. Quach TT, Massicote G, Belin MF, Honnorat J, Glasper ER, Devries AC et al. CRMP3 is required for hippocampal CA1 dendritic organization and plasticity. FASEB J 2008; 2: 401-409.
49. Demyanenko GK, Tsai AY, Maness PF. Abnormalities in neuronal process extension, hippocampal development, and the ventricular system of L1 knockout mice. J Neurosci 1999; 19: 4907-4920.
50. Camdessanche JP, Ferraud K, Boutahar N, Lassabliere F, Mutter M, Touret M et al. The CRMP5 onconeural protein is expressed in Schwann cells under axonal signals and regulates axon-Schwann cell interaction. J Neuropathol Exp Neurol 2012; 71: 298-311.
51. Rapoport JL, Gield JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry 2012; 17: 1228-1238.
52. Penzes P, Cahill ME, Jones KA, Vanderleuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 2011; 14: 285-293.
53. Jones LB, Johnson N, Byne N. Alterations in MAP2 immunocytochemistry in area 9 and 32 of schizophrenic prefrontal cortex. Psychiatry Res 2002; 114: 137-148.
54. Hall J, Trent S, Thomas KL, O'Donovan MC, Owen MJ. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol Psychiatry 2015; 77: 52-58.
55. Bader V, Tomppo L, Trossbach SV, Bradshaw NJ, Prikulis I, Leliveld SR et al. Proteomic, genomic and translational approaches identify CRMP1 for a role in schizophrenia and its underlying traits. Hum Mol Genet 2012; 21: 4406-4418.
56. Quach TT, Glasper ER, Devries AC, Honnorat J, Kolattukudy PE. Altered prepulse inhibition in mice with dendrite abnormalities of hippocampal neurons. Mol Psychiatry 2008; 13: 656-658.
57. Hensley K, Venkova K, Christov A, Gunning W, Park J. CRMP2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 2011; 43: 180-191.
58. Martins de Souza D, Dias-Neto E, Schmitt A, Falkai P, Gormanns P, MacCarrone G et al. Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry 2010; 11: 110-120.
59. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol Psychiatry 2000; 5: 142-149.
60. Edgar PF, Douglas JE, Cooper GJ, Dean B, Kydd R, Faull RL. Comparative pro-teome analysis of the hippocampus implicates chromosome 6q in schizophrenia. Mol Psychiatry 2000; 5: 85-90.
61. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004; 9: 684-697.
62. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics 2006; 6: 3414-3425.
63. Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 2006; 11: 459-470.
64. Pennington K, Dicker P, Dunn MJ, Cotter DR. Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics 2008; 8: 5097-5107.
65. Fallin MD, Lasseter VK, Liu Y, Avramopoulos D, McGrath J et al. Linkage and association on 8p21.2-p21.1 in Schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2011; 156: 188-197.
66. Blouin BA, Dombroski SK, Nath VK, Lasseter VK, Wolyniec PS, Nestadt G et al. Schizophrenia susceptibility loci on chromosomes13q32 and 8p21. Nat Genet 1998; 20: 70-73.
67. Gurling HM, Kalsi G, Brynjolson J, Sigmundsson T, Sherrington R, Mankoo BS et al. Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia on chromosomes 1q32.2, 5q33.2 and 8p21.22 and provides support for linkage to schizophrenia on chromosomes 111q23.3 and 20q21.1-11-23. Am J Hum Genet 2001; 68: 661-673.
68. Holmans PA, Riley B, Pulver AE. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol Psychiatry 2009; 14: 786-795.
69. Nakata K, Ujike H, Sakai A, Takaki M, Imamura T, Tanaka Y et al. The human dihydropyrimidinase-related protein 2 gene on chromosome 8p21 is associated with paranoid-type schizophrenia. Biol Psychiatry 2003; 53: 571-576.
70. Liu Y, Pham X, Zhang L, Chen PL, Burzynski G, McGaughey DM et al. Functional variants in DPYSL2 sequence increase risk of Schizophrenia and suggest a link to mTOR signaling. G3 (Bethesda) 2015; 5: 61-72.
71. Koide T, Aleksic B, Ito Y, Usui H, Yoshimi A, Inada T et al. A two-stage case-control association study of the dihydropyrimidinase-like 2 gene (DPYSL2) with schizophrenia in Japanese subjects. J Hum Genet 2010; 55: 469-472.
72. Föcking M, Dicker P, English JA, Schubert KO, Dunn MJ, Cotter DR. Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Arch Gen Psychiatry 2011; 68: 477-488.
73. Hill MJ, Donocik JG, RA Nuamah, CA Mein. Sainz-Fuertes R1 Transcriptional consequences of schizophrenia candidate miR-137 manipulation in human neural progenitor cells. Schizophr Res. 2014; 153: 225-230.
74. Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci USA 2012; 109: 3125-3130.
75. Kedracka-Krok S, Swiderska B, Jankowska U, Skupien-Rabian B, Solich J, Buczak K et al. Clozapine influences cytoskeleton structure and calcium homeostasis in rat cerebral cortex and has a different proteomic profile than risperidone. J Neuro-chem 2015; 132: 657-676.
76. Pickering C, Ericson M, Söderpalm B. Chronic phencyclidine increases synapsin-1 and synaptic adaptation proteins in the medial prefrontal cortex. ISRN Psychiatry 2013; 620361.
77. Mateus-Pinheiro A, Patrício P, Bessa JM, Sousa N, Pinto L. Cell genesis and dendritic plasticity: a neuroplastic pas de deux in the onset and remission from depression. Mol Psychiatry 2013; 18: 748-750.
78. Dimatelis JJ, Stein DJ, Russel VA. Chronic exposure to light reverses the effect of maternal separation on proteins in the prefrontal cortex. J Mol Neurosci 2013; 51: 835-843.
79. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
80. Molendjik ML, Spinhoven P, Polak M, Elzinger BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analysis on 179 association (N: 9484). Mol Psy 2014; 19: 791-800.
81. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neurplasticity in depression. Int. J. Neuropsychopharmacol 2008; 11: 1169-1180.
82. Wong ML, Dong C, Andreev V, Arcos-Burgos M, Licinio J. Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environment factors. Mol Psychiatry 2012; 17: 624-633.
83. Magarinos AM, Li CJ, Bath KC, Jing FS, Lee FS, McEven BS. Effect of brain-derived neurotrophic factor haploinsufficiency on stress-induced remodeling of hippo-campal neurons. Hippocampus 2011; 21: 253-264.
84. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006; 314: 140-143.
85. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007; 18: 391-418.
86. Khawaja X, Xu J, Liang JJ, Barrett JE. Proteomic analysis of proteins changes developing in rat hippocampus after chronic antidepressants treatment: implications for depressive disorders and future therapies. J Neurosci Res 2004; 75: 451-460.
87. Hensley K, Venkova K, Christov A, Gunning W, Park J. Collapsin response mediator protein 2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol 2011; 43: 180-191.
88. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: Potential therapeutic targets. Science 2012; 338: 68-72.
89. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorders. Nat Genet 2008; 40: 1056-1058.
90. Caberlotto L, Carboni L, Zanderigo F, Andreetta F, Andreoli M, Gentile G et al. Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 893-903.
91. Lyoo IK, Dager SR, Kim JE, Yoon SJ, Friedman SD, Dunner DL et al. Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsycho-pharmacology 2010; 35: 1743-1750.
92. Hajek T, Cullis J, Novak T, Kopecek M, Höschl C, Blagdon R et al. Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord 2012; 14: 261-270.
93. Gildengers AG, Butters MA, Aizenstein HJ, Marron MM, Emanuel J, Anderson SJ et al. Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder. Bipolar Disord 2014; 17: 248-256.
94. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013; 45: 984-994.
95. Frisoni GB, Sabattoli F, Lee AD, Dutton RA, Thompson PM. In vivo neuro-pathology of the hippocampal formation in Alzheimer's disease: a radial mapping MR-based study. Neuroimage 2006; 32: 104-110.
96. Mucke L, Selkoe DJ. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012; 2: 1-17.
97. Lu T, Aron L, Zullo J, Pan Y, Chen Y, Yang TH et al. REST and stress resistance in aging and Alzheimer's disease. Nature 2014; 507: 448-454.
98. Woods NK, Padmanabhan J. Neuronal calcium signaling and Alzheimer disease. Adv Exp Med Biol 2012; 740: 1193-1217.
99. Soutar MP, Thornhill P, Cole AR, Sutherland C. Increased CRMP2 phosphorylation is observed in Alzheimer's disease; does this tell us anything about disease development? Curr Alzheimer Res 2009; 6: 269-278.
100. Cole AR, Noble W, Van Aalten L et al. CRMP2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem 2007; 103: 1132-1144.
101. Williamson R, van Alten L, Mann DM, Platt B, Plattner F, Bedford L et al. CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases. J Alzheimers Dis 2011; 27: 615-625.
102. Wang Y, Yin H, Li J, Zhang Y, Han B, Zeng Z et al. Amelioration of β-amyloid-induced cognitive dysfunction and hippocampal axon degeneration by curcu-min is associated with suppression of CRMP-2 hyperphosphorylation. Neurosci Lett 2013; 557: 112-117.
103. Marshall KE, Marchante R, Serpell LC. The relationship between amyloid structure and cytotoxicity. Prion 2014; 8: 2.
104. Prusiner SB. Biology and genetics of prions causing neurodegeneration. Ann Rev Genet 2013; 47: 601-623.
105. Auvergnon N, Reibel S, Touret M, Honnorat J, Baron T, Giraudon P et al. Altered expression of CRMPs in the brain of bovine spongiform encephalopathy-infected mice during disease progression. Brain Res 2009; 1261: 1-6.
106. Ishikura N, Clever JL, Bouzamondo-Berstein E, Prusiner SB, Huang EJ, DeArmond SJ. Notch-1 activation and dendritic dystrophy in prion disease. Proc Natl Acad Sci USA 2005; 102: 886-891.
107. Shinkai-Ouchi F, Yamakawa Y, Hara H, Tobiume M, Nishijima M, Hagiwara K. Identification and structural analysis of C-terminally truncated CRMP2 in a murine model of prion diseases. Proteome Sci 2010; 8: 53-65.
108. Quach TT, Wang Y, Khanna R, Chounlamountri N, Auvergnon N, Honnorat J et al. Effect of CRMP3 expression on dystrophic dendrites of hippocampal neurons. Mol Psychiatry 2011; 16: 689-691.
109. Hirose S. A new paradigm of channelopathy in epilepsy syndromes: intracellular trafficking abnormality of ion channels dysfunction and channel molecules. Epilepsy Res 2006; 70S: S206-S217.
110. Bonilha L, Nesland T, Martz GU, Joseph JE, Spampinato MW, Tabesh A. Medial temporal lobe epilepsy is associated with neuronal fiber loss and paradoxal increase in structural connectivity in limbic structures. J Neurol Neurosurg Psychiatry 2012; 83: 903-909.
111. Bernhardt BC, Worsley KJ, Besson J, Concha L, Lerch JP, Evans AC et al. Mapping limbic network organization in temporal lobe epilepsy using morphometric correlations insights on the relation between mesiotemporal connectivity and cortical atrophy. Neuroimage 2008; 42: 512-524.
112. DeSalvo MN, Douw L, Tanaka N, Reinsberger C, Stufflebeam SM. Altered structural connectome in temporal lobe epilepsy. Radiology 2014; 270: 842-848.
113. Luo J, Zeng K, Zhang C, Fang M, Zhu Q, Wang L et al. Down-regulation of CRMP1 in patients with epilepsy and a rat model. Neurochem Res 2012; 37: 1381-1391.
114. Czech T, Yang JW, Csaszar E, Kappler J, Baumgardner C, Lubec G. Reduction of hippocampal CRMP2 in patients with mesial temporal lobe epilepsy. Neurochem Res 2004; 29: 2189-2196.
115. Wang Y, Brittain J, Jarecki BW, Wilson S, Wang B, Hale R et al. In silico docking and electrophysiological characterization of Lacosamide binding sites on CRMP2 identifies a pocket important in modulating sodium channels slow inactivation. J Biol Chem 2010; 285: 25296-25307.
116. Bridges D, Thompson SWN, Rice ASC. Mechanisms of neuropathic pain. Br J Anaesthesia 2001; 87: 12-26.
117. Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. Br Med J 2014; 348: f7656.
118. Tan AM, Samad OA, Fischer TZ, Zhao P, Persson AK, Waxman SG. Maladaptive dendritic spine remodeling contributes to diabetic neuropathic pain. J Neurosci 2012; 32: 6795-6807.
119. Kim C, Jun K, Lee T, Kim SS, McEnery MW, Chin H et al. Altered nociceptive response in mice deficient in the alpha(1B) subunit of the voltage-dependent calcium channel. Mol Cell Neurosci 2001; 18: 235-245.
120. Cao YQ. Voltage-gated calcium channels and pain. Pain 2006; 126: 5-9.
121. 2+ channel complex. Nat Med 2011; 17: 822-829.
122. Ju W, Li Q, Allette YM, Ripsch MS, White FA, Khanna R. Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide. J Neurochem 2012; 124: 869-879.
123. (2+) channel complex demonstrates efficacy in animal models of migraine and AIDS therapy-induced neuropathy. Transl Neurosci 2012; 3: 1-8.
124. 2+ channels, attenuation of nociceptor excitability, and anti-noception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol Pain 2012; 8: 1-19.
125. Fischer G, Pan B, Vilceam D, Hogan OH, Yu H. Sustained relief of neuropathic pain by AAV-targeted expression of CBD3 peptide in rat DRG. Gene Ther 2014; 21: 44-51.
126. Petratos S, Ozturk E, Azari MF, Kenny R, Lee JY, Magee KA et al. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phos-phorylation. Brain 2012; 135: 1794-1818.
127. Tsutiya A, Ohtani-Kaneko R. Post-natal alteration of CRMP4 mRNA expression in the mouse brain. J Anat 2012; 221: 341-351.
128. Ricard D, Rogemond V, Charrier E, Bagnard D, Belin MF, Thomasset N et al. Isolation and expression of human Ulip6/CRMP5: coexistence with Ulip2/CRMP2 in Sema3A-sensitive oligodendrocytes. J Neurosci 2001; 21: 7203-7214.
129. Marques JM, Rodrigues RJ, Valbuena S, Rozas JL, Selak S, Marin P et al. CRMP2 tethers kainate receptor activity to cytoskeleton dynamics during neuronal maturation. J Neurosci 2013; 33: 18298-18310.